Read More

Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand

Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity diminish. Analysts foresee potential sales surpassing $85 billion, closely watching competitive landscape.

LLY

Read More

Tesla Analysts Size Up Ugly Q1 Numbers: Disaster, Train Wreck, Horror Show, Nightmare — Will Storm Pass Or Are Darker Days Ahead?

Tesla posted its first year-over-year decline in deliveries since 2020 on Tuesday, which sparked a selloff in shares. The EV maker said the decline in volumes was partially due to the production ramp of the updated Model 3, as well as factory shutdowns resulting from the Red Sea conflict and an arson attack at its German gigafactory.

TSLA

Read More

Historic S&P 500 Rally In Q1 Flashes Bullish Signals For 2024: ‘Only The Ninth Time Since 1940’

The S&P 500 had a 10.6% total return in Q1, following a 22.3% gain since September. This historic streak is driven by strong earnings and economic resilience. Nasdaq predicts continued gains.

AAPL